Istituto Europeo di Oncologia

The Istituto Europeo di Oncologia (IEO) — the European Institute of Oncology — is Italy's leading dedicated oncology hospital, located at Via Ripamonti 435 in southern Milan. Conceived and founded by Professor Umberto Veronesi, one of the most influential oncologists of the twentieth century, the IEO was inaugurated in May 1994 with an ambitious mission: to implement an innovative model for advanced cancer treatment and research, integrating clinical care, translational science, and prevention into a single, purpose-built institution.

Professor Veronesi's foundational vision drew together an internationally diverse faculty from eight European countries, creating from the outset a genuinely European institution rather than a purely Italian one. Division and unit directors represented Germany, France, the Netherlands, the United Kingdom, Sweden, and other European countries alongside Italy, reflecting the IEO's commitment to pan-European expertise and perspective. This international character has been maintained and strengthened over three decades, with the institute continuing to attract leading oncologists, researchers, and clinical scientists from across Europe and globally.

In January 1996, through a Ministerial Decree, the IEO achieved IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico) designation — the Italian government's highest recognition for hospital-based clinical research. This designation acknowledges the IEO as a centre of excellence for both cancer treatment and cancer science, providing access to dedicated national research funding and membership of Italy's prestigious IRCCS research hospital network.

The IEO operates as a non-profit institution under private law and provides services through agreements with Italy's National Health Service (Servizio Sanitario Nazionale — SSN), making a significant proportion of its cancer care accessible to Italian patients through the public healthcare system. This non-profit mission reflects the IEO's founding principle that cancer care and research should serve all cancer patients, not exclusively those with private means.

The IEO is exclusively focused on oncology, providing the full spectrum of cancer diagnosis, treatment, and follow-up within a dedicated cancer-only environment that enables deep multidisciplinary specialization.

Breast oncology is the IEO's most internationally recognized area of expertise, reflecting Prof. Veronesi's own lifetime contribution to breast cancer surgery and treatment. The institute was pivotal in establishing the clinical evidence for breast-conserving surgery (lumpectomy) as an alternative to mastectomy for early breast cancer — a paradigm shift in oncology whose influence transformed breast cancer treatment globally. Today the breast surgery program performs breast-conserving procedures, sentinel lymph node biopsy, nipple-sparing mastectomy, oncoplastic techniques, and prophylactic surgery for BRCA mutation carriers, underpinned by a comprehensive multidisciplinary breast unit.

Surgical oncology encompasses hepato-biliary and pancreatic surgery, esophagogastric surgery, colorectal surgery, urological oncology (prostate, bladder, kidney), gynecological oncology (ovarian, endometrial, cervical cancers), thoracic oncology (lung, pleural, mediastinal tumors), and sarcoma surgery. Minimally invasive and robotic oncological surgical approaches are widely employed.

Medical oncology provides precision oncology protocols including targeted therapy, immunotherapy (checkpoint inhibitors, CAR-T for appropriate hematological malignancies), and clinical trial access. Radiation oncology delivers advanced radiotherapy techniques including IMRT, stereotactic body radiotherapy (SBRT), intraoperative radiotherapy (IORT), and proton therapy coordination. Haemato-oncology, oncological dermatology, and a comprehensive cancer prevention and early detection program based on Prof. Veronesi's lifelong research in prevention complete the IEO's clinical portfolio.

The IEO operates from a purpose-built oncology campus at Via Ripamonti 435 in Milan, designed specifically to support the integration of clinical cancer care with translational research. The hospital's physical environment reflects a deliberate design philosophy prioritizing patient dignity, clinical functionality, and the proximity of research laboratories to clinical wards to enable rapid translation of scientific discoveries into clinical practice.

Surgical theatres are equipped for complex oncological surgery across all specialties, including dedicated robotic surgery suites (da Vinci Surgical System), minimally invasive laparoscopic platforms, intraoperative radiotherapy (IORT) delivery systems, and specialized surgical equipment for complex hepato-biliary, thoracic, and gynecological oncological procedures. Intensive care units support post-operative recovery for high-complexity surgical patients.

The radiation oncology department is equipped with linear accelerators delivering IMRT, VMAT, IGRT, stereotactic radiosurgery, and SBRT. An intraoperative radiotherapy (IORT) capability allows radiation to be delivered directly to the tumor bed at the time of surgery — a technique with which the IEO has accumulated extensive experience, particularly in breast cancer. The diagnostic imaging department provides MRI (including 3T systems), CT, PET-CT, digital mammography, breast MRI, and ultrasonography.

The IEO's research infrastructure is one of its most distinctive features, with translational oncology and molecular biology laboratories co-located with clinical facilities. The research program encompasses genomics, proteomics, biomarker discovery, clinical trial design and delivery, and cancer epidemiology. The IEO is a member of multiple European cancer clinical trial networks (EORTC, BCIRG, others), providing patients with access to cutting-edge experimental therapies.

The IEO's European founding identity and internationally diverse faculty make it a naturally welcoming institution for international patients seeking cancer treatment in Milan. The institute's particular excellence in breast cancer, surgical oncology, and advanced radiotherapy attracts patients from across Europe, the Middle East, and beyond who are seeking a second oncological opinion or specialist treatment not available in their home country.

The IEO offers international oncological second opinions, reviewing medical records, pathology reports, imaging, and treatment history to provide expert recommendations on diagnosis, staging, or treatment alternatives. This service is particularly valued by international patients who have received a cancer diagnosis at home and wish to confirm their treatment plan or explore alternative options before proceeding.

Patient coordinators with English language capability support international patients through appointment scheduling, medical record coordination, and communication with specialist teams. Milan is one of Europe's most accessible cities for international travelers, served by Malpensa International Airport (with extensive transatlantic and European connections) and Linate Airport (serving European capitals). The IEO's location in southern Milan is accessible by metro, taxi, and private transfer from both airports.

Costs for international self-pay patients reflect the IEO's position as a private non-profit institution working within the Italian healthcare system. Treatment costs are generally more competitive than equivalent private cancer hospitals in Switzerland, Germany, or the UK, while delivering research-hospital levels of oncological expertise and access to clinical trial programs.

The Istituto Europeo di Oncologia holds the IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico) designation from the Italian Ministry of Health — the country's highest recognition for hospital-based clinical research. Awarded in January 1996 through Ministerial Decree, this designation certifies the IEO as a national center of excellence for both oncological clinical care and biomedical research, and provides access to dedicated Ministry of Health research funding. IRCCS status is maintained through periodic scientific review of the institute's research output and clinical excellence.

As a non-profit private institution providing services to the Italian NHS (SSN), the IEO operates under licensing and oversight by the Italian Ministry of Health and the Lombardy Regional Health Authority (ATS Milano). All clinical facilities, medical staff qualifications, and care standards are subject to national and regional inspection and regulatory oversight.

The IEO participates in multiple international oncology research networks, including the EORTC (European Organisation for Research and Treatment of Cancer), confirming its recognition within the pan-European cancer research community. The institute's clinical research output — thousands of peer-reviewed publications and hundreds of clinical trials — represents ongoing external validation of its scientific and clinical excellence. The founding association with Prof. Umberto Veronesi, a recipient of numerous international science prizes and honors, and the continued involvement of internationally recruited faculty, affirm the IEO's standing as a truly European center of oncological excellence.